Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1097/FJC.0000000000000208

http://scihub22266oqcxt.onion/10.1097/FJC.0000000000000208
suck pdf from google scholar
C4355033!4355033 !25636068
unlimited free pdf from europmc25636068
    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25636068 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid25636068
      J+Cardiovasc+Pharmacol 2015 ; 65 (3 ): 226-32
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • AT2 receptor activities and pathophysiological implications #MMPMID25636068
  • Matavelli LC ; Siragy HM
  • J Cardiovasc Pharmacol 2015[Mar]; 65 (3 ): 226-32 PMID25636068 show ga
  • Although angiotensin II subtype-2 receptor (AT2R) was discovered over 2 decades ago, its contribution to physiology and pathophysiology is not fully elucidated. Current knowledge suggests that under normal physiologic conditions, AT2R counterbalances the effects of angiotensin II subtype-1 receptor (AT1R). A major obstacle for AT2R investigations was the lack of specific agonists. Most of the earlier AT2R studies were performed using the peptidic agonist, CG42112A, or the nonpeptidic antagonist PD123319. CGP42112A is nonspecific for AT2R and in higher concentrations can bind to AT1R. Recently, the development of specific nonpeptidic AT2R agonists boosted the efforts in identifying the therapeutic potentials for AT2R stimulation. Unlike AT1R, AT2R is involved in vasodilation by the release of bradykinin and nitric oxide, anti-inflammation, and healing from injury. Interestingly, the vasodilatory effects of AT2R stimulation were not associated with significant reduction in blood pressure. In the kidney, AT2R stimulation produced natriuresis, increased renal blood flow, and reduced tissue inflammation. In animal studies, enhanced AT2R function led to reduction of cardiac inflammation and fibrosis, and reduced the size of the infarcted area. Similarly, AT2R stimulation demonstrated protective effects in vasculature and brain.
  • |*Drug Design [MESH]
  • |*Molecular Targeted Therapy [MESH]
  • |Animals [MESH]
  • |Anti-Inflammatory Agents/pharmacology [MESH]
  • |Brain/*drug effects/metabolism/pathology/physiopathology [MESH]
  • |Cardiovascular Agents/pharmacology [MESH]
  • |Cardiovascular System/*drug effects/metabolism/pathology/physiopathology [MESH]
  • |Fibrosis [MESH]
  • |Humans [MESH]
  • |Kidney/*drug effects/metabolism/pathology/physiopathology [MESH]
  • |Neuroprotective Agents/pharmacology [MESH]
  • |Receptor, Angiotensin, Type 2/*agonists/metabolism [MESH]
  • |Renin-Angiotensin System/*drug effects [MESH]
  • |Signal Transduction/drug effects [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box